INTENSITY THERAPEUTICS, INC. Proceeds from Long-Term Debt Issued
INTENSITY THERAPEUTICS, INC. (INTS) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2025-03-13
- INTENSITY THERAPEUTICS, INC. proceeds from issuance of long-term debt for the quarter ending 2024-12-31 was $0.00.
- INTENSITY THERAPEUTICS, INC. proceeds from issuance of long-term debt for the quarter ending 2024-09-30 was $0.00.
- INTENSITY THERAPEUTICS, INC. proceeds from issuance of long-term debt for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. proceeds from issuance of long-term debt for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2023 was $230.00K, a 89.78% decline from fiscal 2022.
- INTENSITY THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2022 was $2.25M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | -$13.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | -$13.00K derived: sum of 3 quarters · filed 2025-03-13 | -$13.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | -$13.00K derived: sum of 2 quarters · filed 2025-03-13 | -$13.00K derived: sum of 3 quarters · filed 2025-03-13 | $25.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$13.00K derived: sum of 2 quarters · filed 2025-03-13 | $25.00K derived: sum of 3 quarters · filed 2025-03-13 | $230.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $38.00K derived: sum of 2 quarters · filed 2024-11-13 | $243.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $243.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $205.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $2.25M 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |